Frank Ruffo
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Frank Ruffo
Earlier roles on record: CFO at Aclaris Therapeutics, Inc. (ACRS) until December 31, 2022. Aclaris Therapeutics, Inc. reported in an 8-K filed November 22, 2022 that Frank Ruffo retired as Chief Financial Officer and Corporate Secretary, effective December 31, 2022. The proxy statement of Aclaris Therapeutics, Inc. reports total compensation of $3,262,768 for Frank Ruffo in fiscal 2021, including a base salary of $401,700. Disclosed compensation is on record for 3 fiscal years.
“On November 21, 2022, Mr. Ruffo notified the Company that he will retire from his positions as Chief Financial Officer and Corporate Secretary of the Company, effective December 31, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2022-12-31
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | $401,700 | $3,262,768 |
| 2020 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | $390,000 | $811,609 |
| 2019 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | $390,000 | $1,162,390 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.